leadf
logo-loader
viewShield Therapeutics PLC
(
LSE:STXFRA:1JS
)

Shield Therapeutics takes bold approach in the US

Snapshot

  • Shield Therapeutics pleased with progress to date on US launch of Accrufer
  • Shield Therapeutics' present drive for US launch success of iron deficiency product Accrufer
Shield Therapeutics PLC -

Quick facts: Shield Therapeutics PLC

Follow
LSE:STX

Price: 41.18 GBX

Market Cap: £88.9 m

About the company

Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the company is currently in the process of selecting a commercialisation partner for the US market. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.

How it is doing

17 Aug 2021

Shield Therapeutics PLC (LSE:STX, FRA:1JS) (LSE:STX) said in its half-year results that the focus in the second half will be on the roll-out of its iron deficiency product Accrufer in the US.

The product was launched in the US on 1 July, so the only impact it had on the company’s results for the first six months of the year was as an expense as the company prepared for the launch.

During the second quarter of 2021, the company built up a sales force and started to contact key prescribers. Due to the ongoing impact of the COVID pandemic and the emergence of the delta variant in the US, face-to-face contact with clinicians has been limited in the initial phase of launch but discussions are taking place with payers regarding formulary placement of Accrufer and will continue over the next several months.

The focus in the US will be on building awareness among healthcare providers, initiating prescriptions for appropriate patients to generate clinical experience and extending patient access through negotiations with payer groups.

12 Aug 2021

Shield Therapeutics PLC (LSE:STX, FRA:1JS) shares surged on Thursday as it said it has secured a licence agreement in South Korea for its Accrufer iron deficiency therapy.

Under the deal with Korea Pharma Co Ltd, the company said it will receive an upfront payment of £0.5mln and is also eligible to receive a further £1.5mln upon the first commercial sale of Accrufer in Korea.

09 Aug 2021

Shield Therapeutics PLC (LSE:STX, FRA:1JS) (LON:STX) has flagged up research in a leading academic publication showcasing some “very exciting” results from a study involving its lead product.

Investigators assessed the potential of Feraccru (known as Accrufer in the US, and also called ferric maltol).

What management says

17 Aug 2021

Shield Therapeutics PLC (LSE:STX, FRA:1JS) (LSE:STX) new CEO Greg Madison talks to Proactive London about his strategy for the company and focus on driving the iron deficiency product Accrufer in the US.

The product was launched in the US on 1 July, so the only impact it had on the company’s results for the first six months of the year was as an expense as the company prepared for the launch.

During the second quarter of 2021, the company built up a sales force and started to contact key prescribers. Due to the ongoing impact of the COVID pandemic and the emergence of the delta variant in the US, face-to-face contact with clinicians has been limited in the initial phase of launch but discussions are taking place with payers regarding formulary placement of Accrufer and will continue over the next several months.

Proactive Research

25 Aug 2021

Shield’s investment proposition is very simple: it hinges on its US success in commercialising Accrufer (US brand) to treat iron deficient anaemia using its own 30-person salesforce and a striking ad campaign. Shield owns the product, takes all the profit but, most importantly, controls the process.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Shield Therapeutics' on cusp of US market expansion with focus on...

Shield Therapeutics PLC (LSE:STX, FRA:1JS)'s (LON:STX, OTCQX:SHIEF) investment case is presented by Proactive Research Analyst John Savin who explains how the firm hinges on the success of their US launch of commercialising Accrufer. This treatment is for iron deficiency or anaemia and as...

3 weeks, 2 days ago

3 min read